Table 2.
Histologic picture of early indication biopsies (n=329)
| Histological Characteristic | Prevalence in Early Indication Biopsies (n=329), n (%) | Biopsies with DGF (n=127) | Biopsies without DGF (n=202) |
|---|---|---|---|
| Rejection phenotypes (Banff 2017) | |||
| No rejection | 143 (43%) | 63 (50%) | 80 (40%) |
| Borderline changes | 31 (9%) | 7 (6%) | 24 (12%) |
| Acute T cell–mediated rejection | 95 (29%) | 33 (26%) | 62 (31%) |
| Antibody-mediated rejection | 14 (4%) | 3 (2%) | 11 (5%) |
| Mixed rejection (TCMR and ABMR) | 46 (14%) | 21 (17%) | 25 (12%) |
| Histologic lesion scores | |||
| Glomerulitis >0; >1 | 88 (27%); 57 (17%) | 37 (29%); 27 (21%) | 51 (25%); 30 (15%) |
| Peritubular capillaritis >0; >1 | 118 (36%); 59 (18%) | 50 (39%); 23 (18%) | 68 (34%); 36 (18%) |
| Microvascular inflammation (g+ptc) ≥2 | 99 (30%) | 41 (32%) | 58 (29%) |
| C4d deposition ptc >0; >1 | 94 (29%); 58 (18%) | 37 (29%); 21 (17%) | 57 (28%); 37 (18%) |
| Tubulitis >0; >1 | 185 (56%); 74 (22%) | 67 (53%); 25 (20%) | 118 (58%); 49 (24%) |
| Interstitial inflammation >0; >1 | 157 (48%); 101 (31%) | 54 (43%); 36 (28%) | 103 (51%); 65 (32%) |
| Tubulointerstitial score ≥ 2 | 162 (49%) | 56 (44%) | 105 (52%) |
| Intimal arteritis >0; >1 | 119 (36%); 18 (5%) | 52 (41%); 8 (6%) | 67 (33%); 10 (5%) |
| Vascular intimal thickening >0; >1 | 138 (42%); 53 (16%) | 52 (41%); 23 (18%) | 86 (43%); 30 (15%) |
| Arteriolar hyalinosis >0; >1 | 90 (27%); 32 (10%) | 26 (20%); 8 (6%) | 64 (32%); 24 (12%) |
| Tubular atrophy >0; >1 | 155 (47%); 9 (3%) | 52 (41%); 4 (3%) | 103 (51%); 5 (2%) |
| Intimal fibrosis >0; >1 | 41 (12%); 12 (4%) | 14 (11%); 5 (4%) | 27 (13%); 7 (3%) |
| Thrombi | 18 (5%) | 4 (3%) | 14 (7%) |
| Transplant glomerulopathy >0; | 1 (0.3%) | 0 | 1 (0.5%) |
| Mesangial matrix expansion >0; >1 | 14 (4%); 5 (2%) | 4 (3%) | 10 (5%) |
DGF, delayed graft function; TCMR, T cell-mediated rejection; ABMR, antibody-mediated rejection; g, glomerulitis; ptc, peritubular capillaritis.